![Marit Sjo Lorentzen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marit Sjo Lorentzen
Geschäftsführer bei ARCTICZYMES TECHNOLOGIES ASA
Vermögen: 49 562 $ am 31.05.2024
Aktive Positionen von Marit Sjo Lorentzen
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ARCTICZYMES TECHNOLOGIES ASA | Geschäftsführer | - | - |
Direktor/Vorstandsmitglied | - | - | |
Biotec BetaGlucans AS
![]() Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Marit Sjo Lorentzen
Ausbildung von Marit Sjo Lorentzen
University of Tromso | Undergraduate Degree |
Statistik
International
Norwegen | 4 |
Operativ
Director/Board Member | 2 |
Chief Operating Officer | 1 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ARCTICZYMES TECHNOLOGIES ASA | Health Technology |
Private Unternehmen | 1 |
---|---|
Biotec BetaGlucans AS
![]() Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Health Technology |
- Börse
- Insiders
- Marit Sjo Lorentzen
- Erfahrung